Home > Compound List > Compound details
7261-97-4 molecular structure
click picture or here to close

1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione

ChemBase ID: 1089
Molecular Formular: C14H10N4O5
Molecular Mass: 314.253
Monoisotopic Mass: 314.06511944
SMILES and InChIs

SMILES:
o1c(c2ccc([N+](=O)[O-])cc2)ccc1/C=N/N1CC(=O)NC1=O
Canonical SMILES:
O=C1CN(C(=O)N1)/N=C/c1ccc(o1)c1ccc(cc1)[N+](=O)[O-]
InChI:
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)
InChIKey:
OZOMQRBLCMDCEG-UHFFFAOYSA-N

Cite this record

CBID:1089 http://www.chembase.cn/molecule-1089.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
IUPAC Traditional name
dantroleno
sodium, dantrolene
Brand Name
Dantrium
Dantrium Intravenous
Synonyms
Dantrolene Sodium
Dantroleno [INN-Spanish]
Dantrolenum [INN-Latin]
Dantrolene
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
CAS Number
7261-97-4
MDL Number
MFCD00867709
PubChem SID
160964552
PubChem CID
2952
6914273
CHEBI ID
4317
ATC CODE
M03CA01
CHEMBL
1201288
Chemspider ID
2847
DrugBank ID
DB01219
IUPHAR ligand ID
4172
KEGG ID
D02347
Unique Ingredient Identifier
F64QU97QCR
Wikipedia Title
Dantrolene

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
Enamine
EN300-119181 external link Add to cart Please log in.

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 9.233154  H Acceptors
H Donor LogD (pH = 5.5) 1.2564061 
LogD (pH = 7.4) 1.2502273  Log P 1.2564855 
Molar Refractivity 78.8745 cm3 Polarizability 29.878029 Å3
Polar Surface Area 120.73 Å2 Rotatable Bonds
Lipinski's Rule of Five true 
Log P 1.65  LOG S -3.59 
Solubility (Water) 8.05e-02 g/l 

PROPERTIES

PROPERTIES

Physical Property Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
Low (146 mg/L) expand Show data source
Hydrophobicity(logP)
1.631 expand Show data source
1.7 expand Show data source
Admin Routes
Oral, intravenous expand Show data source
Bioavailability
70% expand Show data source
Excretion
Biliary, renal expand Show data source
Metabolism
Liver expand Show data source
Pregnancy Category
C (US) expand Show data source
Purity
95% expand Show data source

DETAILS

DETAILS

DrugBank DrugBank Wikipedia Wikipedia
DrugBank - DB01219 external link
Item Information
Drug Groups approved
Description Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Indication For use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
Pharmacology Dantrolene is classified as a direct-acting skeletal muscle relaxant. It is currently the only specific and effective treatment for malignant hyperthermia. In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates excitation-contraction coupling, probably by interfering with the release of Ca2+ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In selected humans, it has been postulated that “triggering agents” (e.g.,general anesthetics and depolarizing neuromuscular blocking agents) produce a change within the cell which results in an elevated myoplasmic calcium. This elevated myoplasmic calcium activates acute cellular catabolic processes that cascade to the malignant hyperthermia crisis. It is hypothesized that addition of Dantrium to the “triggered” malignant hyperthermic muscle cell reestablishes a normal level of ionized calcium in the myoplasm.
Toxicity Oral LD50 in rats is 7400 mg/kg. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic, most likely by hepatic microsomal enzymes. Its major metabolites in body fluids are 5-hydroxydantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrium may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.
Absorption Bioavailability is 70%.
Half Life The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.
Protein Binding Significant, mostly to albumin.
References
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • • Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. Pubmed
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle